45.24
2.54%
-1.125
Legend Biotech Corp ADR Aktie (LEGN) Neueste Nachrichten
Morgan Stanley cuts Legend Biotech shares target, cites revised sales forecast - Investing.com
Investing.com
Morgan Stanley cuts Legend Biotech shares target, cites revised sales forecast By Investing.com - Investing.com UK
Investing.com UK
Market Watch: Legend Biotech Corp ADR (LEGN)'s Noteworthy Gain, Closing at 44.38 – DWinneX - The Dwinnex
The Dwinnex
Investing in Legend Biotech Corp ADR (LEGN) might be a great opportunity, but the stock is a bit overvalued – US Post ... - US Post News
US Post News
Legend Biotech shares price target trimmed to $86 by H.C. Wainwright - Investing.com South Africa
Investing.com South Africa
Legend Biotech shares price target trimmed to $86 by H.C. Wainwright - Investing.com
Investing.com
Legend Biotech shares target raised by RBC on growth prospects - Investing.com
Investing.com
A better buy-in window may exist right now for Legend Biotech Corp ADR (LEGN) – Sete News - SETE News
SETE News
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Benzinga
Earnings call: Legend Biotech reports robust growth with CARVYKTI - Investing.com
Investing.com
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights - Investing.com India
Investing.com India
Should You Buy Legend Biotech (LEGN) Ahead of Earnings? - Yahoo Finance
Yahoo Finance
Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar? - Yahoo News UK
Yahoo News UK
Legend Biotech (LEGN) in Focus: Stock Moves 6.2% Higher - Yahoo Singapore News
Yahoo Singapore News
Legend Biotech Corp ADR (LEGN) presents a great opportunity, but the stock is slightly overvalued – US Post News - US Post News
US Post News
Should investors be concerned about Legend Biotech Corp ADR (LEGN)? – US Post News - US Post News
US Post News
Analyst Ratings For Legend Biotech
Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
Benzinga
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Zacks Investment Research
Why Legend Biotech (LEGN) Stock Might be a Great Pick
Zacks Investment Research
Why Legend Biotech (LEGN) Stock Might be a Great Pick - Yahoo Finance
Yahoo Finance
Cantor Fitzgerald bullish on Legend Biotech stock, starts coverage at Overweight - Investing.com
Investing.com
Unveiling 9 Analyst Insights On Legend Biotech
Benzinga
Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
MarketWatch
BMO maintains $90 target on Legend Biotech shares amid approval optimism - Investing.com
Investing.com
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Benzinga
Company News for Mar 12, 2024
Zacks Investment Research
Earnings call: Legend Biotech reports strong CARVYKTI sales, expansion plans - Investing.com
Investing.com
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Zacks Investment Research
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys - Yahoo Finance
Yahoo Finance
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Zacks Investment Research
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024 - Zacks Investment Research
Zacks Investment Research
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Benzinga
What 4 Analyst Ratings Have To Say About Legend Biotech
Benzinga
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
Zacks Investment Research
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Benzinga
Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Seeking Alpha
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Benzinga
Key Takeaways From Legend Biotech Analyst Ratings
Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Benzinga
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
Zacks Investment Research
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
Zacks Investment Research
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
MarketWatch
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Zacks Investment Research
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
The Motley Fool
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
InvestorPlace
Legend Biotech Stock: Carvykti Approval Makes For A Buy Opportunity (NASDAQ:LEGN) - Seeking Alpha
Seeking Alpha
Kapitalisierung:
|
Volumen (24h):